Shay Capital’s ADMA Biologics ADMA Stock Holding History

Shay Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,504	Closed	-$43K	–	425
2022 Q1	$43K	Sell	23,504 -5,900	-20%	-$9.2K	0.01%	455
2021 Q4	$41K	Buy	+29,404	New	+$38.7K	0.01%	437
2021 Q3	–	Sell	-159,614	Closed	-$255K	–	525
2021 Q2	$255K	Buy	159,614 +38,952	+32%	+$68.5K	0.03%	370
2021 Q1	$212K	Buy	120,662 +70,662	+141%	+$162K	0.02%	359
2020 Q4	$98K	Buy	+50,000	New	+$105K	0.02%	260

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Shay Capital's ADMA Position: Q2 2022 in Review

Shay Capital sold out of ADMA Biologics (ADMA) in Q2 2022, closing a stake of 23,504 shares — an estimated $43K sold.

Shay Capital first reported a position in ADMA in Q4 2020 and held it in 5 quarters. The position peaked at $255K in Q2 2021. 113 funds tracked by Wall St. Rank hold ADMA as of Q2 2022.

Shay Capital reported no remaining ADMA Biologics position as of Q2 2022 after selling out during the quarter.
Shay Capital sold 23,504 ADMA Biologics shares in Q2 2022, an estimated $43K.
Shay Capital first reported a position in ADMA Biologics in Q4 2020 and held it in 5 quarters.
Shay Capital's ADMA Biologics position peaked at $255K in Q2 2021.
113 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2022.

Based on Shay Capital's 13F filing for Q2 2022, filed 15 Aug 2022.